Angeliki Bolou

Dr. Angeliki Bolou


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 November 2023 in BMJ Open
Verified
Journal Article
Open access
PDF file
ABAngeliki Bolou
Angeliki Bolou
ZDZoe Drymoussi
Zoe Drymoussi
DLDoris Lanz
Doris Lanz
CAChiamaka Esther Amaefule
Chiamaka Esther Amaefule
FCFrancisco Jose Gonzalez Carreras
Francisco Jose Gonzalez Carreras
STShakila Thangaratinam
Shakila Thangaratinam
Objective To determine the feasibility of a definitive trial of metformin to prevent type 2 diabetes in the postnatal period in women with gestational diabetes. Design A multicentre, placebo-controlled, double-blind randomised feasibility trial with qualitative evaluation. Setting Three inner-city UK National Health Service hospitals in London. Participants Pregnant women with gestational diabetes treated with medication. Interventions 2 g of metformin (intervention) or placebo (control) from delivery until 1 year postnatally. Primary outcome measures Rates of recruitment, randomisation, follow-up, attrition and adherence to the intervention. Secondary outcome measures Preliminary estimates of glycaemic effects, qualitative exploration, acceptability of the intervention and costs. Results Out of 302 eligible women, 57.9% (175/302) were recruited. We randomised 82.3% (144/175) of those recruited, with 71 women in the metformin group and 73 women in the placebo group. Of the participants remaining in the study and providing any adherence information, 54.1% (59/109) took at least 75% of the target intervention dose; the overall mean adherence was 64% (SD 33.6). Study procedures were found to be acceptable to women and healthcare professionals. An increased perceived risk of developing type 2 diabetes, or a positive experience of taking metformin during pregnancy, encouraged participation and adherence to the intervention. Barriers to adherence included disruption to the medication schedule caused by the washout periods ahead of each study visit or having insufficient daily reminders. Conclusions It is feasible to run a full-scale definitive trial on the effectiveness of metformin to prevent type 2 diabetes in women with gestational diabetes, during the early postnatal period. Adherence and engagement with the study could be improved with more regular reminders and potentially the addition of ongoing educational or peer support to reinforce messages around type 2 diabetes prevention. Trial registration number ISRCTN20930880.

17 May 2020 in BMJ Open
Verified
Journal Article
Open access
PDF file
CAChiamaka Esther Amaefule
Chiamaka Esther Amaefule
ABAngeliki Bolou
Angeliki Bolou
ZDZoe Drymoussi
Zoe Drymoussi
FCFrancisco Jose Gonzalez Carreras
Francisco Jose Gonzalez Carreras
MLMaria del Carmen Pardo Llorente
Maria del Carmen Pardo Llorente
STShakila Thangaratinam
Shakila Thangaratinam
Introduction Up to half of all women diagnosed with gestational diabetes mellitus develop type 2 diabetes within 5 years after delivery. Metformin is effective in preventing type 2 diabetes in high-risk non-pregnant individuals, but its effect when commenced in the postnatal period is not known. We plan to assess the feasibility of evaluating metformin versus placebo in minimising the risk of dysglycaemia including type 2 diabetes after delivery in postnatal women with a history of gestational diabetes through a randomised trial. Methods and analysis Optimising health outcomes with Metformin to prevent diAbetes After pregnancy (OMAhA) is a multicentre placebo-controlled double-blind randomised feasibility trial, where we will randomly allocate 160 postnatal women with gestational diabetes treated with medication to either metformin (intervention) or placebo (control) tablets to be taken until 1 year after delivery. The primary outcomes are rates of recruitment, randomisation, adherence and attrition. The secondary outcomes are maternal dysglycaemia, cost and quality of life outcomes in both arms, and acceptability of the study and intervention, which will be evaluated through a nested qualitative study. Feasibility outcomes will be summarised using descriptive statistics, point estimates and 95% CIs. Ethics and dissemination The OMAhA study received ethics approval from the London-Brent Research Ethics Committee (18/LO/0505). Trial findings will be published in a peer-reviewed journal, disseminated at conferences, through our Patient and Public Involvement advisory group (Katie’s Team) and through social media platforms. Trial registration number ISRCTN20930880

30 December 2021 in BMJ Open
Verified
Journal Article
Open access
PDF file
ABAngeliki Bolou
Angeliki Bolou
DLDoris Lanz
Doris Lanz
ZDZoe Drymoussi
Zoe Drymoussi
FCFrancisco Jose Gonzalez Carreras
Francisco Jose Gonzalez Carreras
FAFrances Austin
Frances Austin
STShakila Thangaratinam
Shakila Thangaratinam
Introduction Women with gestational diabetes are at increased risk of developing type 2 diabetes later in life. In at-risk general populations, Mediterranean-style diet helps prevent type 2 diabetes. But its effect on postnatal women with a history of gestational diabetes is not known. Prior to a full-scale trial on Mediterranean-style diet in the postnatal period to prevent type 2 diabetes, a feasibility study is required to assess the acceptability of the diet and evaluate the trial processes. Methods and analysis MEditerranean diet for pReventIon of type 2 diabeTes is a single-arm feasibility study (65 women) with qualitative evaluation of women who have recently given birth and had gestational diabetes. The intervention is a Mediterranean-style diet supplemented with nuts and olive oil, with dietary advice and an action plan. A dedicated Health Coach will interact with participants through an interactive lifestyle App. Women will follow the intervention from 6 to 13 weeks post partum until 1 year post partum. The primary outcomes are rates of recruitment, follow-up, adherence and attrition. The secondary outcomes are maternal dysglycaemia, cost and quality of life outcomes, and acceptability of the intervention to participants, and to healthcare professionals delivering the intervention. Feasibility outcomes will be reported using descriptive statistics. Ethics and dissemination Ethical approval was obtained through the South Central—Berkshire Research Ethics Committee (19/SC/0064). Study findings will be disseminated via publication in peer-reviewed journals, as well as via newsletters made available to participants and members of Katie’s Team (a women’s health patient and public advisory group). Trial registration number ISRCTN40582975.

4 August 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
Alina LiepinaitienėAlina Liepinaitienė
Alina Liepinaitienė
NANikolaos S. Avramiotis
Nikolaos S. Avramiotis
Dimitra MetallinouDimitra Metallinou
Dimitra Metallinou
ABAngeliki Bolou
Angeliki Bolou
MTMaria Tzeli
Maria Tzeli
Antigoni SarantakiAntigoni Sarantaki
Antigoni Sarantaki
Climate change is increasing the frequency and intensity of extreme heat events, raising concern about prenatal thermal exposure as a potential risk factor for fetal brain development and offspring neurodevelopment. This systematic review aimed to synthesize evidence on prenatal heat exposure, placental inflammatory or stress-response pathways, and neurodevelopmental outcomes in offspring. A systematic literature search was conducted in PubMed/MEDLINE, Scopus, Web of Science, Google Scholar and Embase from database inception to 30 June 2026. Human observational studies, animal experiments and in vitro mechanistic studies were included when they examined prenatal or early-life heat exposure in relation to placental function, inflammatory or oxidative pathways, fetal brain development or offspring neurodevelopment. The included evidence linked prenatal heat exposure or maternal hyperthermia with neural tube defects, neurodevelopmental delay, language impairment, autism spectrum disorder, cerebral palsy and altered brain morphology. Early pregnancy appeared to be the most consistent vulnerability window, although later gestational exposure was also relevant. Experimental evidence suggested disruption of placental barrier function, glucocorticoid and serotonin signaling, inflammatory and oxidative pathways, myelination, apoptosis, and neural progenitor development. Prenatal heat exposure may contribute to neurodevelopmental vulnerability through a heat-related placenta–brain axis. Further prospective and mechanistic studies are needed.

14 October 2026 in Cancer Plus
Verified
Journal Article
Open access
PDF file
ATAlexios Tsochrinis
Alexios Tsochrinis
PPPanagiota Pappou
Panagiota Pappou
KGKleanthi Gourounti
Kleanthi Gourounti
EPERMIONI PALASKA
ERMIONI PALASKA
ADANNA DELTSIDOU
ANNA DELTSIDOU
ABAnastasia Bothou
Anastasia Bothou
Breast cancer during pregnancy presents unique therapeutic challenges, as effective maternal treatment must be balanced against potential risks to fetal and neonatal health. This systematic review aims to evaluate current evidence regarding the safety and effectiveness of chemotherapy during pregnancy in women with breast cancer (BC). This systematic review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. A comprehensive literature search was conducted in PubMed, Google Scholar, Scopus, and the Open Inter-university Consortium for Political and Social Research databases. Following the search and selection process, a total of 14 articles met the inclusion criteria. Risk of bias was assessed using design-specific Joanna Briggs Institute critical appraisal tools. The administration of specific chemotherapy regimens, mainly anthracyclines, after the first trimester was generally not associated with an apparent increase in congenital abnormalities or perinatal mortality. However, an increased risk of preterm birth was observed, with a substantial proportion of preterm deliveries being iatrogenic. Furthermore, available comparative evidence did not indicate substantially worse maternal oncological outcomes attributable to pregnancy itself. Taken together, these findings suggest that chemotherapy for BC during pregnancy can be administered with relative safety after the first trimester, within an individualized treatment approach and close collaboration among obstetricians, oncologists, and neonatologists. Nevertheless, further multicenter studies are required to fully elucidate long-term neonatal outcomes.

31 August 2026 in Pediatric Reports
Verified
Journal Article
Open access
PDF file
VHVikentia Harizopoulou
Vikentia Harizopoulou
ABAngeliki Bolou
Angeliki Bolou
ETEvdoxia Tsiakiri
Evdoxia Tsiakiri
MBMARIA BOUROUTZOGLOU
MARIA BOUROUTZOGLOU
VVVictoria Vivilaki
Victoria Vivilaki
Dimitra MetallinouDimitra Metallinou
Dimitra Metallinou
Background/Objectives: Preterm birth remains a significant global public health challenge, associated with increased morbidity, rehospitalisation, and long-term vulnerability. The transition from the neonatal intensive care unit (NICU) to the home environment represents a critical phase. This practice-focused narrative review synthesises current evidence on community-based post-discharge follow-up for preterm infants, with particular emphasis on the complementary contribution of community health nursing and midwifery within multidisciplinary follow-up models, endocrine-metabolic surveillance and coordinated care for medically complex infants. Methods: A narrative synthesis of review articles, clinical guidelines, and empirical studies published between 2015 and 2026 was undertaken. Searches were performed in PubMed, Scopus, and CINAHL using terms related to preterm birth, NICU discharge, community follow-up, family-centred care, community health nursing, midwifery, and metabolic disorders. Results: Community-based, family-centred follow-up programmes are associated with improved continuity of care, increased parental confidence, enhanced breastfeeding outcomes, and reduced healthcare utilisation. Community health nurses, midwives and health visitors contribute complementary expertise within multidisciplinary follow-up by coordinating continuity of care, providing clinical surveillance of growth and feeding, supporting caregiver education, facilitating early identification of complications, and ensuring timely referral. However, endocrine and metabolic vulnerabilities remain underrepresented in many follow-up models, while infants with complex healthcare needs require individualised, risk-stratified surveillance. Conclusions: Community-based, interdisciplinary, and family-centred follow-up after NICU discharge is essential to enhance the quality and safety of care for preterm infants. Integrated, risk-stratified models of follow-up that combine preventive surveillance, family education, multidisciplinary coordination, and continuity of care may facilitate earlier recognition of complications and improve long-term outcomes.